Clinical Pharmacokinetics

, Volume 28, Issue 5, pp 385–404 | Cite as

Clinical Pharmacokinetics and Pharmacodynamics of Opioid Analgesics in Infants and Children

  • Klaus T. Olkkola
  • Katri Hamunen
  • Eeva-Liisa Maunuksela
Review Article Clinical Pharmacokinetics in Special Populations


Pain in childhood has not always been managed as actively as that in adults because of the limited amount of research available to provide guidelines for the management of paediatric pain. However, for many years now the pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children have been studied intensively.

Morphine is the standard for opioid analgesics and its pharmacology is the best studied in paediatric patients. During the neonatal period, the volume of distribution (Vd) appears to be smaller in neonates than in adults, but adult values are reached soon after the neonatal period. Although morphine is absorbed both orally and rectally, there is little information on the pharmacokinetics of morphine administered by these routes. The bioavailability of morphine after rectal administration appears to be highly variable.

For all the opioid analgesics studied, the elimination of the opioids is slower in neonates than in adults. However, the rate of elimination usually reaches and even exceeds adult values within the first year of life. The high rate of drug metabolism means higher dosage requirements. In regard to the pharmacodynamics of opioid analgesics, infants and children do not appear to be more sensitive to the effects of opioids than adults. Thus, except for the neonatal period, the pharmacokinetics and pharmacodynamics of opioid analgesics are not markedly different from those of adults, and the risk of using opioids in infants and children is not higher.


Morphine Fentanyl Adis International Limited Buprenorphine Oxycodone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Maunuksela E-L, Olkkola KT. Pediatric pain management. Int Anesthesiol Clin 1991; 29: 37–55PubMedGoogle Scholar
  2. 2.
    Radde IC. Mechanisms of drug absorption and their development. In: Macleod SM, Radde IC, editors. Textbook of pediatric clinical pharmacology. Littleton: PSG Publishing Company, 1985: 17–31Google Scholar
  3. 3.
    Welling PG. Interactions affecting drug absorption. Clin Pharmacokinet 1984; 9: 404–34PubMedGoogle Scholar
  4. 4.
    Celander O. Studies of the peripheral circulation. In: Cassels D, editor. The heart and circulation in the newborn. New York: Grune and Stratton, 1966: 98–110Google Scholar
  5. 5.
    Friis-Hansen B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics 1961; 28: 169–81PubMedGoogle Scholar
  6. 6.
    Brook CDG. Cellular growth: adipose tissue. In: Falkner F, Tanner JM, editors. Human growth: postnatal growth. 2nd ed. New York, London: Plenum Press, 1978: 21–33Google Scholar
  7. 7.
    Radde IC. Drugs and protein binding. In: Macleod SM, Radde IC, editors. Textbook of pediatric clinical pharmacology. Littleton: PSG Publishing Company, 1985: 32–43Google Scholar
  8. 8.
    Pelkonen O, Kaltiala EH, Larmi TKI, et al. Comparison of activities of drug metabolizing enzymes in human fetal and adult livers. Clin Pharmacol Ther 1973; 14: 840–6PubMedGoogle Scholar
  9. 9.
    Pokela M-L, Olkkola KT, Seppälä T, et al. Age-related morphine kinetics in infants. Dev Pharm Ther 1993; 20: 26–34Google Scholar
  10. 10.
    Stanski DR, Greenblatt DJ, Lowenstein E. Kinetics of intravenous and intramuscular morphine. Clin Pharmacol Ther 1978; 24: 52–9PubMedGoogle Scholar
  11. 11.
    Neims AH. Renal elimination of drugs at various ages. In: Turner P, editor. Clinical pharmacology and therapeutics. Proceedings of the First World Conference. London: Macmillan, 1980: 117–123Google Scholar
  12. 12.
    Besunder JB, Reed MD, Blumer JL. Principles of drug bio-disposition in the neonate: a critical evaluation of the pharmacokinetic-pharmacodynamic interface. Clin Pharmacokinet 1988; 14: 189–286PubMedGoogle Scholar
  13. 13.
    Kaufmann JJ, Semo NM, Koski WS. Mircoelectrometric titration measurement of the pKas and partition and drug distribution coefficients of narcotics and narcotic antagonist and their pH and temperature dependence. J Med Chem 1975; 18: 647–55Google Scholar
  14. 14.
    Bhat R, Chari G, Gulati A, et al. Pharmacokinetics of a single dose of morphine in preterm infants during the first week of life. J Pediatr 1990; 117: 477–81PubMedGoogle Scholar
  15. 15.
    McRorie TI, Lynn AM, Nespeca MK, et al. The maturation of morphine clearance and metabolism. Am J Dis Child 1992; 146: 972–6PubMedGoogle Scholar
  16. 16.
    Olsen GD. Morphine binding to human plasma proteins. Clin Pharmacol Ther 1975; 17: 31–5PubMedGoogle Scholar
  17. 17.
    Greene RF, Miser AW, Lester CM, et al. Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys. Pain 1987; 30: 339–48PubMedGoogle Scholar
  18. 18.
    Barret DA, Elias-Jones AC, Ruttner N, et al. Morphine kinetics after diamorphine infusion in premature neonates. Br J Clin Pharm 1991; 32: 31–7Google Scholar
  19. 19.
    Chay PC, Duffy BJ, Walker JS. Pharmacokinetic-pharmacodynamic relationships of morphine in neonates. Clin Pharmacol Ther 1992; 51: 334–42PubMedGoogle Scholar
  20. 20.
    Choonara IA, McKay P, Hain R, et al. Morphine metabolism in children. Br J Clin Pharm 1989; 28: 599–604Google Scholar
  21. 21.
    Koren G, Butt W, Chinyanga H, et al. Postoperative morphine infusion in newborn infants: assessment of disposition characteristics and safety. J Pediatr 1985; 107: 963–7PubMedGoogle Scholar
  22. 22.
    Lynn AM, Slattery JT. Morphine pharmacokinetics in early infancy. Anesthesiology 1987; 66: 136–9PubMedGoogle Scholar
  23. 23.
    Choonara I, Lawrence A, Michaelkiewicz A, et al. Morphine metabolism in neonates and infants. Br J Clin Pharm 1992; 34: 434–7Google Scholar
  24. 24.
    Dahlström B, Bolme P, Feychting H, et al. Morphine kinetics in children. Clin Pharmacol Ther 1979; 26: 354–65PubMedGoogle Scholar
  25. 25.
    Olkkola KT, Maunuksela E-L, Korpela R, et al. Kinetics and dynamics of postoperative morphine in children. Clin Pharmacol Ther 1988; 44: 128–36PubMedGoogle Scholar
  26. 26.
    Vandenberghe H, MacLeod S, Chiyanga H, et al. Pharmacokinetics of intravenous morphine in balanced anesthesia: studies in children. Drug Metab Rev 1983; 14: 887–903PubMedGoogle Scholar
  27. 27.
    Nahata MC, Miser AW, Miser JS, et al. Variation in morphine pharmacokinetics in children with cancer. Dev Pharmacol Ther 1985; 8: 182–8PubMedGoogle Scholar
  28. 28.
    Owen JA, Sitar SD, Berger L, et al. Age-related morphine kinetics. Clin Pharmacol Ther 1983; 34: 364–8PubMedGoogle Scholar
  29. 29.
    Bhat R, Abu-Harb M, Chari G, et al. Morphine metabolism in acutely ill preterm newborn infants. J Pediatr 1992; 120: 795–9PubMedGoogle Scholar
  30. 30.
    Hartley R, Green M, Quinn M, et al. Pharmacokinetics of morphine infusion in premature neonates. Arch Dis Child 1993; 69: 55–8PubMedGoogle Scholar
  31. 31.
    Hartley R, Quinn M, Green M, et al. Morphine glucuronidation in premature infants. Br J Clin Pharm 1993; 35: 314–7Google Scholar
  32. 32.
    Brunk SF, Delle M. Morphine metabolism in man. Clin Pharmacol Ther 1974; 16: 51–7PubMedGoogle Scholar
  33. 33.
    Dagan O, Klein J, Bohn D, et al. Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. J Cardiothorac Vasc Anesth 1993; 7: 396–8PubMedGoogle Scholar
  34. 34.
    Shelly MP, Cory EP, Park GR. Pharmacokinetics of morphine in two children before and after liver transplation. Br J Anaesth 1986; 58: 1218–23PubMedGoogle Scholar
  35. 35.
    Nahata MC, Miser AW, Miser JS, et al. Analgesic plasma concentrations of morphine in children with terminal malignancy receiving a countinuous infusion of morphine sulfate to control severe pain. Pain 1984; 18: 109–14PubMedGoogle Scholar
  36. 36.
    Nahata MC. Plasma concentrations of morphine in children with chronic pain — comparison of controlled release and regular morphine sulphate tablets. J Clin Pharmacol Ther 1991; 16: 193–5Google Scholar
  37. 37.
    Lindahl S, Olsson A-K, Thomson D. Rectal premedication in children: use of diazepam, morphine and hyoscine. Anaesthesia 1981; 36: 376–9PubMedGoogle Scholar
  38. 38.
    Lundeberg S, Olsson GL, Beck O, et al. Bioavailability of rectally administered morphine in children: a comparative study of a morphine gel and a solution [abstract]. International Association for the Study of Pain, 7th World Congress; 1993 Aug 22–27: ParisGoogle Scholar
  39. 39.
    Westerling D. Rectally administered morphine: plasma concentrations in children premedicated with morphine in hydrogel and in solution. Acta Anaesthesiolo Scand 1985; 29: 653–6Google Scholar
  40. 40.
    Gourlay GK, Boas RA. Fatal outcome with use of rectal moprhine for postoperative pain control in an infant. BMJ 1992; 304: 766–7PubMedGoogle Scholar
  41. 41.
    Attia J, Ecoffey C, Sandouk P, et al. Epidural morphine in children: pharmacokinetics and CO2 sensitivity. Anesthesiology 1988; 65: 590–4Google Scholar
  42. 42.
    Nordberg G, Hedner T, Meilstrand T, et al. Pharmacokinetic aspects of epidural morphine analgesia. Anesthesiology 1983; 58: 545–51PubMedGoogle Scholar
  43. 43.
    Wolf AR, Hughes D, Hobbs AJ, et al. Combined morphinebupivacaine caudals for reconstructive penile surgery in children: systemic absorbtion of morphine and postoperative analgesia. Anaesth Intensive Care 1991; 19: 17–21PubMedGoogle Scholar
  44. 44.
    Nichols DG, Yaster M, Lynn AM, et al. Disposition and respiratory effects of intrathecal morphine in children. Anesthesiology 1993; 79: 733–8PubMedGoogle Scholar
  45. 45.
    Lynn AM, Opheim KE, Tyler DC. Morphine infusion after pediatric cardiac surgery. Crit Care Med 1984; 12: 863–6PubMedGoogle Scholar
  46. 46.
    Dahlström B, Tamsen A, Paalzow L, et al. Patient-controlled analgesic therapy, part IV: pharmacokinetics and analgesic plasma concentrations of morphine. Clin Pharmacokinet 1982; 7: 266–79PubMedGoogle Scholar
  47. 47.
    Way WL, Costley EC, Way EL. Respiratory sensitivity of the newborn infant to meperidine and morphine. Clin Pharmacol Ther 1965; 6: 454–61PubMedGoogle Scholar
  48. 48.
    Lynn AM, Nespeca MK, Opheim KE, et al. Respiratory effects of intravenous morphine infusions in neonates, infants, and children after cardiac surgery. Anesth Analg 1993; 77: 695–701PubMedGoogle Scholar
  49. 49.
    Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Goodman Gilman A, et al. (eds): The pharmacological basis of therapeutics. New York: Pergamon Press, 1990; 485–531Google Scholar
  50. 50.
    Meuldermans WEG, Hurkmans RMA, Heykants JJP. Plasma protein binding of fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int Pharmacodyn Ther 1982; 257: 4–19PubMedGoogle Scholar
  51. 51.
    Nation RL. Meperidine binding in maternal and fetal plasma. Clin Pharmacol Ther 1981; 29: 472–9PubMedGoogle Scholar
  52. 52.
    Atwood GF, Evans MA, Harbison RD. Pharmacokinetics of meperidine in infants [abstract]. Pediatr Res 1976; 10: 328Google Scholar
  53. 53.
    Edwards DJ, Svenson CK, Visco JP, et al. Clinical pharmacokinetics of pethidine: 1982. Clin Pharmacokinet 1982; 7: 421–33PubMedGoogle Scholar
  54. 54.
    McMorland GH, Douglas MJ. Systemic medication in labour and delivery. In: Ostheimer GW, editor. Clinics in anesthesiology. Vol. 4: obstetric analgesia and anesthesia I. London: WB Saunders Company, 1986: 81–91Google Scholar
  55. 55.
    Belfrage P, Boréus LO, Hartvig P, et al. Neonatal depression after obstetrical analgesia with pethidine: the role of the injection-delivery time interval and of the plasma concentra tions of pethidine and norpethidine. Acta Obstet Gynecol Scand 1981; 60: 43–9PubMedGoogle Scholar
  56. 56.
    Caldwell J, Notarianni LJ, Smith RL. Impaired metabolism of pethidine in the human neonate. Br J Clin Pharm 1978; 5: 362–3Google Scholar
  57. 57.
    Caldwell J, Wakile LA, Notarianni LJ, et al. Maternal and neonatal disposition of pethidine in childbirth — a study using quantative gas chromatgrahpy-mass spectrometry. Life Sci 1978; 22: 589–96PubMedGoogle Scholar
  58. 58.
    Cooper LV, Stephen GW, Aggett PJA. Elimination of pethidine and bupivacaine in the newborn. Arch Dis Child 1977; 52: 638–41PubMedGoogle Scholar
  59. 59.
    Kuhnert BR, Kuhnert PM, Tu A-SL, et al. Meperidine and normeperidine levels following meperidine administration during labor: II. Fetus and neonate. Am J Obstet Gynecol 1979; 133: 909–14PubMedGoogle Scholar
  60. 60.
    Kuhnert BR, Kuhnert PM, Philipson EH, et al. Disposition of meperidine and normeperidine following multiple doses during labor. Am J Obstet Gynecol 1985b; 151: 410–5PubMedGoogle Scholar
  61. 61.
    Morrison JC, Wiser WL, Rosser SI, et al. Metabolites of meperidine related to fetal depression. Am J Obstet Gynecol 1973; 115: 1132–7PubMedGoogle Scholar
  62. 62.
    Morrison JC, Whybrew WD, Rosser SI, et al. Metabolite of meperidine in the fetal and maternal serum. Am J Obstet Gynecol 1976; 120: 997–1002Google Scholar
  63. 63.
    Hogg MIJ, Wiener PC, Rosen M, et al. Urinary excretion and metabolism of pethidine and norpethidine in the newborn. Br J Anaesth 1977; 49: 891–9PubMedGoogle Scholar
  64. 64.
    Morselli PL, Rovei V. Placental transfer of pethidine and norpethidine and their pharmacokinetics in the newborn. Eur J Clin Pharmacokinet 1980; 18: 25–30Google Scholar
  65. 65.
    Pokela M-L, Olkkola KT, Koivisto M, et al. Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants. Clin Pharmacol Ther 1992a; 52: 342–9PubMedGoogle Scholar
  66. 66.
    Hamunen K, Maunuksela E-L, Seppälä T, et al. Pharmacokinetics of i.v. and rectal pethidine in children undergoing ophthalmic surgery. Br J Anaesth 1993; 71: 823–6PubMedGoogle Scholar
  67. 67.
    Koska AJ, Kramer WG, Romagnoli A, et al. Pharmacokinetics of high dose meperidine in surgical patients. Anesth Analg 1981; 60: 8–11PubMedGoogle Scholar
  68. 68.
    Mather LE, Tucker GT, Pflug AE, et al. Meperidine kinetics in man: intravenous injection in surgical patients and volunteers. Clin Pharmacol Ther 1975; 17: 21–30PubMedGoogle Scholar
  69. 69.
    Tamsen A, Hartvig P, Fagerlund C, et al. Patient-controlled analgesic therapy, part I: pharmacokinetics of pethidine in the pre- and postoperative periods. Clin Pharmacokinet 1982; 7: 149–63PubMedGoogle Scholar
  70. 70.
    Kuhnert BR, Kuhnert PM, Prochaska AL, et al. Meperidine disposition in mother, neonate, and nonpregnant females. Clin Pharmacol Ther 1980; 27: 486–91PubMedGoogle Scholar
  71. 71.
    Asatoor AM, London DR, Milne MD, et al. The excretion of pethidine and its derivatives. Br J Pharmacol 1963; 20: 285–98Google Scholar
  72. 72.
    Szeto HH, Inturrisi CE, Houde R, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 1977; 86: 738–40PubMedGoogle Scholar
  73. 73.
    Wainer IW, Stambaugh JE. GLC determination of meperidinic acid and nor-meperidinic acids in urine. J Pharm Sci 1978; 67: 116–7PubMedGoogle Scholar
  74. 74.
    Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983; 13: 180–5PubMedGoogle Scholar
  75. 75.
    Jacobsen J, Flachs H, Dich-Nielsen JO, et al. Comparative plasma concentration profiles after i.V., i.m. and rectal administration of pethidine in children. Br J Anaesth 1988; 60: 623–6PubMedGoogle Scholar
  76. 76.
    Austin KL, Stapleton JV, Mather LE. Multiple intramuscular injections: a major source of variability in analgesic response to meperidine. Pain 1980; 8: 47–60PubMedGoogle Scholar
  77. 77.
    Austin KL, Stapleton JV, Mather LE. Relationship between blood meperidine concentrations and analgesic response: a preliminary report. Anesthesiology 1980; 53: 460–6PubMedGoogle Scholar
  78. 78.
    Kuhnert BR, Linn PL, Kennard MJ, et al. Effects of low doses of meperidine on neonatal behavior. Anesth Analg 1985a; 64: 335–42PubMedGoogle Scholar
  79. 79.
    Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 1991; 41: 326–44PubMedGoogle Scholar
  80. 80.
    Maunuksela E-L, Korpela R, Olkkola KT. Double-blind, multiple-dose comparison of buprenorphine and morphine in postoperative pain of children. Br J Anaesth 1988; 60: 48–55PubMedGoogle Scholar
  81. 81.
    Maunuksela E-L, Korpela R, Olkkola KT. Comparison of buprenorphine with morphine in the treatment of postoperative pain in children. Anesth Analg 1988; 67: 233–9PubMedGoogle Scholar
  82. 82.
    Olkkola KT, Maunuksela E-L, Korpela R. Pharmacokinetics of intravenous buprenorphine in children. Br J Clin Pharm 1989; 28: 202–4Google Scholar
  83. 83.
    Bullingham RES, McQuay HJ, Moore A, et al. Buprenorphine kinetics. Clin Pharmacol Ther 1980; 28: 667–72PubMedGoogle Scholar
  84. 84.
    Berde CB, Beyer JE, Bournaki M-C, et al. Comparison of morphine and methadone for prevention of postoperative pain in 3- to 7-year-old children. J Pediatr 1991; 119: 136–41PubMedGoogle Scholar
  85. 85.
    Gourlay GK, Wilson PR, Glynn CJ. Pharmacodynamics and pharmacokinetics of methadone during perioperative period. Anesthesiology 1982; 57: 458–67PubMedGoogle Scholar
  86. 86.
    Olkkola KT, Hamunen K, Seppälä T, et al. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. Br J Clin Pharm 1994; 38: 71–6Google Scholar
  87. 87.
    Pöyhiä R, Seppälä T, Olkkola KT, et al. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharm 1992; 33: 617–21Google Scholar
  88. 88.
    Hamunen K, Olkkola KT, Seppälä T, et al. Ventilatory effects and kinetics of intravenous pentazocine in children. Pharmacol Toxicol 1993; 72: 120–3Google Scholar
  89. 89.
    Berkowitz BA, Asling JH, Shnider SM, et al. Relationship of pentazocine plasma levels to pharmacological activity in man. Clin Pharmacol Ther 1969; 10: 320–8PubMedGoogle Scholar
  90. 90.
    Ehrnebo M, Boreus LO, Lönroth U. Bioavailability and first-pass metabolism of oral pentazocine in man. Clin Pharmacol Ther 1977; 22: 888–92PubMedGoogle Scholar
  91. 91.
    Bullingham RES, McQuay HJ, Porter EJB, et al. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol 1982; 13: 665–73PubMedGoogle Scholar
  92. 92.
    Hamunen K, Olkkola KT, Maunuksela E-L. Comparison of ventilatory effects of morphine and buprenorphine in children. Acta Anaesthesiol Scand 1993; 37: 449–53PubMedGoogle Scholar
  93. 93.
    Gourlay GK, Willis RJ, Wilson PR. Postoperative pain control with methadone: influence of supplementary methadone doses and blood concentration-response relationship. Anesthesiology 1984; 61: 19–26PubMedGoogle Scholar
  94. 94.
    Ferrer-Brechner T, Ganz P. Combination therapy with ibuprofen and methadone for chronic cancer pain. Am J Med 1984; 77: 78–83PubMedGoogle Scholar
  95. 95.
    Maunuksela E-L, Saarinen UM, Lähteenoja K-M. Prevalence and management of terminal pain in children with cancer: five-year experience in Helsinki, Finland. In: Tyler DC, Crane EJ, editors. Advances in pain research and therapy. Vol. 15. New York: Raven Press, 1990; 383–90Google Scholar
  96. 96.
    Berde CB, Sethna NF, Holzman RS, et al. Pharmacokinetics of methadone in children and adolescents in the perioperative period [abstract]. Anesthesiology 1987; 67: A519Google Scholar
  97. 97.
    Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 1986; 25: 297–312PubMedGoogle Scholar
  98. 98.
    Hamunen K. Ventilatory effects of morphine, pethidine and methadone in children. Br J Anaesth 1993; 70: 414–8PubMedGoogle Scholar
  99. 99.
    Kalso E, Pöyhiä R, Onnela P, et al. Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 1991; 35: 642–6PubMedGoogle Scholar
  100. 100.
    Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990; 47: 639–46PubMedGoogle Scholar
  101. 101.
    Reynolds JEF, editor. Martindale: the extra pharmacopeia. 30th ed. London: Pharmaceutical Press, 1993; 1315Google Scholar
  102. 102.
    Pöyhiä R, Seppälä T. Lipid solubility and protein binding of oxycodone in vitro. Pharmacol Toxicol 1994; 74: 23–7PubMedGoogle Scholar
  103. 103.
    Pöyhiä R, Olkkola KT, Seppälä T, et al. The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharm 1991; 32: 516–8Google Scholar
  104. 104.
    Leow KP, Smith MT, Williams B, et al. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992; 52: 487–95PubMedGoogle Scholar
  105. 105.
    Saarialho-Kere U, Mattila MJ, Seppälä T. Psychomotor, respiratory and neuroendocrinological effects of a μ-opioid receptor agonist (oxycodone) in healthy volunteers. Pharmacol Toxicol 1989; 65: 252–7PubMedGoogle Scholar
  106. 106.
    Chen ZR, Irvine RJ, Somogyi AA, et al. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48: 2165–71PubMedGoogle Scholar
  107. 107.
    Kalso E, Vainio A, Mattila MJ, et al. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 1990; 67: 322–8PubMedGoogle Scholar
  108. 108.
    Brogden RN, Speight TM, Avery GS. Pentazocine: a review of its pharmacological properties, therapeutic efficacy and dependence liability. Drugs 1973; 5: 6–91PubMedGoogle Scholar
  109. 109.
    Iisalo EUM, Iisalo E. A comparison of high dose pentazocine with pethidine and dizepam in paediatric premedication. Ann Chir Gynecol 1978; 67: 123–8Google Scholar
  110. 110.
    Rita L, Cox JM, Seleny FL, et al. Ketamine hydrochloride for pediatric premedication: comparison with pentazocine. Anesth Analg 1974; 53: 375–9PubMedGoogle Scholar
  111. 111.
    Waterworth TA. Pentazocine (Fortral) as postoperative analgesic in children. Arch Dis Child 1974; 49: 488–90PubMedGoogle Scholar
  112. 112.
    Ehrnebo M, Agurell S, Boreus LO, et al. Pentazocine binding to blood cells and plasma proteins. Clin Pharmacol Ther 1974; 16: 424–9PubMedGoogle Scholar
  113. 113.
    Beckett AH, Kourounakis P, Vaughan DP, et al. The absorption, blood concentrations and excretion of pentazocine after oral, intramuscular or rectal administration to man. J Pharm Pharmacol 1970; 22 Suppl.: 169s–74sGoogle Scholar
  114. 114.
    Bailey PL, Stanley TH. Narcotic intravenous anesthetics. In: Miller RD, editor. Anesthesia. 3rd ed. New York: Churchill Livingstone, 1990: 281–366Google Scholar
  115. 115.
    Collins C, Koren G, Cream P et al. Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. Anesth Analg 1985; 64: 1078–80PubMedGoogle Scholar
  116. 116.
    Roth B, Schlünder C, Houben F, et al. Analgesia and sedation in neonatal intensive care using fentanyl by continuous infusion. Dev Pharmacol Ther 1991; 17: 121–7PubMedGoogle Scholar
  117. 117.
    Johnson KL, Erickson JP, Holley FO, et al. Fentanyl pharmacokinetics in the pediatric population [abstract]. Anesthesiology 1984; 61(3A): A441Google Scholar
  118. 118.
    Koehntop DE, Rodamn JH, Brundage DM, et al. Pharmacokinetics of fentanyl in neonates. Anesth Analg 1986; 65: 227–32PubMedGoogle Scholar
  119. 119.
    Gauntlett IS, Fisher DM, Hertzka RE, et al. Pharmacokinetics of fentanyl in neonatal humans and lambs: effects of age. Anesthesiology 1988; 69: 683–7PubMedGoogle Scholar
  120. 120.
    Singleton MA, Rosen JI, Fisher DM. Pharmacokinetics of fentanil in infants and adults [abstract]. Anesthesiology 1984; 61(3A): A440Google Scholar
  121. 121.
    Koren G, Goresky G, Crean P, et al. Pediatric fentanyl dosing based on pharmacokinetics during cardiac surgery. Anesth Analg 1984; 63: 577–82PubMedGoogle Scholar
  122. 122.
    Bentley JB, Borel JD, Nenad RE, et al. Age and fentanyl kinetics. Anesth Analg 1982; 61: 968–71PubMedGoogle Scholar
  123. 123.
    McClain DA, Hug Jr CC. Intravenous fentanyl kinetics. Clin Pharmacol Ther 1980; 28: 106–14PubMedGoogle Scholar
  124. 124.
    Davis PJ, Killian A, Stiller RL, et al. Pharmacokinetics of alfentanil in newborn premature infants and older children. Dev Pharmacol Ther 1989; 13: 21–7PubMedGoogle Scholar
  125. 125.
    Killian A, Davis PJ, Stiller RL, et al. Influence of gestational age on pharmacokinetics of alfentanil in neonates. Dev Pharmacol Ther 1990; 15: 82–5PubMedGoogle Scholar
  126. 126.
    Marlow N, Weindling AM, Peer A, et al. Alfentanil pharmacokinetics in preterm infants. Arch Dis Child 1990; 65: 349–51PubMedGoogle Scholar
  127. 127.
    Pokela M-L, Ryhänen PT, Koivisto ME, et al. Alfentanil-induced rigidity in newborn infants. Anesth Analg 1992b; 75: 252–7PubMedGoogle Scholar
  128. 128.
    Goresky GV, Koren G, Sabourin MA, et al. The pharmacokinetics of alfentanil in children. Anesthesiology 1987; 67: 654–9PubMedGoogle Scholar
  129. 129.
    den Hollander JM, Hennis PJ, Burm AG, et al. Alfentanil in infants and children with congenital heart defects. J Cardiothorac Anesth 1988; 2: 12–7Google Scholar
  130. 130.
    Davis PJ, Stiller RL, Cook DR, et al. Effects of cholestatic hepatic disease and chronic renal failure on alfentanil pharmacokinetics in children. Anesth Analg 1989; 68: 579–83PubMedGoogle Scholar
  131. 131.
    den Hollander JM, Hennis PJ, Burm AG, et al. Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery. Part I. J Cardiothorac Vasc Anesth 1992; 6: 308–12Google Scholar
  132. 132.
    Mesistelman C, Saint-Maurice C, Lepaul M, et al. A comparison of alfentanil pharmacokinetics in children and adults. Anesthesiology 1987; 66: 13–6Google Scholar
  133. 133.
    Roure P, Lean N, Leclerc AC, et al. Pharmacokinetics of alfentanil in children undergoing surgery. Br J Anaesth 1987; 59: 1437–40PubMedGoogle Scholar
  134. 134.
    Camu F, Gepts E, Rucquoi M, et al. Pharmacokinetics of alfentanil in man. Anesth Analg 1982; 61: 657–61PubMedGoogle Scholar
  135. 135.
    Schüttler J, Stoeckel H. Alfentanil (R 29209) ein neues kurzwirkendes Opioid: Pharmakokinetik und erste klinische Erfarungen. Anaesthesist 1982; 31: 10–14PubMedGoogle Scholar
  136. 136.
    Greeley WJ, de Bruijn NP. Changes in sufentanil pharmacokinetics within the neonatal period. Anesth Analg 1988; 67: 86–90PubMedGoogle Scholar
  137. 137.
    Greeley WJ, de Bruijn NP, Davis DP. Sufentanil pharmacokinetics in pediatric cardiovascular patients. Anesth Analg 1987; 66: 1067–72PubMedGoogle Scholar
  138. 138.
    Davis PJ, Cook DR, Stiller RL, et al. Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. Anesth Analg 1987; 66: 203–8PubMedGoogle Scholar
  139. 139.
    Guay J, Gaudreault P, Tang A, et al. Pharmacokinetics of sufentanil in normal children. Can J Anaesth 1992; 39: 14–20PubMedGoogle Scholar
  140. 140.
    Davis PJ, Stiller RL, Cook DR, et al. Pharmacokinetics of sufentanil in adolescent patients with chronic renal failure. Anesth Analg 1988; 67: 268–71PubMedGoogle Scholar
  141. 141.
    Bovill JG, Sebel PS, Blackburn CL, et al. The pharmacokinetics of sufentanil in surgical patients. Anesthesiology 1984; 61: 502–6PubMedGoogle Scholar
  142. 142.
    Koren G, Goresky G, Crean P, et al. Unexpected alterations in fentanyl pharmacokinetics in children undergoing cardiac surgery: age related or disease related? Dev Pharmacol Ther 1986; 9: 183–91PubMedGoogle Scholar
  143. 143.
    Koren G, Crean P, Goresky GV, et al. Pharmacokinetics of fentanyl in children with renal disease. Res Commun Chem Pathol Pharmacol 1984; 46: 371–9PubMedGoogle Scholar
  144. 144.
    Gourlay GK, Kowalski SR, Plummer JL, et al. Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. Anesth Analg 1988; 67: 329–37PubMedGoogle Scholar
  145. 145.
    Cartwright P, Prys-Roberts C, Gill K, et al. Ventilatory depression related to plasma fentanyl concentrations during and after anesthesia in humans. Anesth Analg 1983; 62: 966–74PubMedGoogle Scholar
  146. 146.
    Hertzka RE, Gaunlett IS, Fisher DM, et al. Fentanyl-induced ventilatory depression: effects of age. Anesthesiology 1989; 70: 213–8PubMedGoogle Scholar
  147. 147.
    Rautiainen P. Alfentanil infusion for sedation in infants and small children during cardiac catherization. Can J Anaesth 1991; 38: 980–4PubMedGoogle Scholar
  148. 148.
    Ausems ME, Hug CC, Stanski DR, et al. Plasma concentrations of alfentanil to supplement nitrous oxide anesthesia for general surgery. Anesthesiology 1986; 65: 362–3PubMedGoogle Scholar
  149. 149.
    Meistelman C, Benhamou D, Barre J, et al. Effects of age on plasma protein binding of sufentanil. Anesthesiology 1990; 72: 470–3PubMedGoogle Scholar
  150. 150.
    Laurijsen K, van-Houdt J, van-Dyck D, et al. Biotransformation of sufentanil in liver microsomes of rats, dogs and humans. Drug Metab Dispos 1990; 18: 704–10Google Scholar
  151. 151.
    Meuldermans W, Hendrickx J, Lauwers W, et al. Excretion and biotransformation of alfentanil and sufentanil in rats and dogs. Drug Metab Dispos 1987; 15: 905–13PubMedGoogle Scholar
  152. 152.
    Haynes G, Brahen NH, Hill HF. Plasma sufentanil concentration after intranasal administration to paediatric outpatients. Can J Anaesth 1993; 40: 286PubMedGoogle Scholar
  153. 153.
    Benlabed M, Ecoffey C, Levron J-C, et al. Analgesia and ventilatory response to CO2 following epidural sufentanil in children. Anesthesiology 1987; 67: 948–51PubMedGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Klaus T. Olkkola
    • 1
  • Katri Hamunen
    • 2
  • Eeva-Liisa Maunuksela
    • 2
  1. 1.Department of AnaesthesiaUniversity of HelsinkiHelsinkiFinland
  2. 2.Helsinki University Eye HospitalHelsinkiFinland

Personalised recommendations